JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M410787200 on November 22, 2004

J. Biol. Chem., Vol. 280, Issue 8, 7228-7235, February 25, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/8/7228    most recent
M410787200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chattopadhyay, A.
Right arrow Articles by Carrington, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chattopadhyay, A.
Right arrow Articles by Carrington, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Structure of the C-terminal Domain from Trypanosoma brucei Variant Surface Glycoprotein MITat1.2*

Anasuya Chattopadhyay{ddagger}§, Nicola G. Jones{ddagger}, Daniel Nietlispach{ddagger}, Peter R. Nielsen{ddagger}, H. Paul Voorheis¶, Helen R. Mott, Recipient of a Career Development Award from the Medical Research Council{ddagger}||, and Mark Carrington{ddagger}**

From the {ddagger}Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, United Kingdom and the Department of Biochemistry, Trinity College, Dublin 2, Ireland

Received for publication, September 20, 2004 , and in revised form, November 22, 2004.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The variant surface glycoprotein (VSG) of African trypanosomes has a structural role in protecting other cell surface proteins from effector molecules of the mammalian immune system and also undergoes antigenic variation necessary for a persistent infection in a host. Here we have reported the solution structure of a VSG type 2 C-terminal domain from MITat1.2, completing the first structure of both domains of a VSG. The isolated C-terminal domain is a monomer in solution and forms a novel fold, which commences with a short {alpha}-helix followed by a single turn of 310-helix and connected by a short loop to a small anti-parallel {beta}-sheet and then a longer {alpha}-helix at the C terminus. This compact domain is flanked by two unstructured regions. The structured part of the domain contains 42 residues, and the core comprises 2 disulfide bonds and 2 hydrophobic residues. These cysteines and hydrophobic residues are conserved in other VSGs, and we have modeled the structures of two further VSG C-terminal domains using the structure of MITat1.2. The models suggest that the overall structure of the core is conserved in the different VSGs but that the C-terminal {alpha}-helix is of variable length and depends on the presence of charged residues. The results provided evidence for a conserved tertiary structure for all the type 2 VSG C-terminal domains, indicated that VSG dimers form through interactions between N-terminal domains, and showed that the selection pressure for sequence variation within a conserved tertiary structure acts on the whole of the VSG molecule.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
African trypanosomes have evolved a complex system of antigenic variation that facilitates the long term survival of a population in a mammalian host (see Ref. 1 for a recent review). The entire cell surface is covered with a densely packed monolayer of a single polypeptide, the variant surface glycoprotein (VSG),1 which protects other cell surface components from effectors of the host immune system. The VSG is also the mediator of antigenic variation. At any time, only a single VSG gene is expressed, and antigenic variation results from a low frequency, stochastic event that causes a switch to the expression of a different VSG gene. During the course of an infection, there are successive clonal expansions of trypanosomes, each expressing an antigenically novel VSG.

In Trypanosoma brucei and the closely related species T. evansi and T. equiperdum, each VSG monomer has a molecular mass of 45–55 kDa and is made up of two or three domains (2, 3). The VSG N-terminal domain has 350–400 residues, which are followed by one or two C-terminal domains of 30–70 residues each. Less is known about T. congolense and T. vivax VSGs; they are somewhat smaller, 45–50 kDa, and have a single domain that is similar to the T. brucei VSG N-terminal domain (4). VSGs are dimeric (5, 6) and are attached to the plasma membrane via a covalent linkage from the C-terminal carboxyl group to a glycosylphosphatidylinositol anchor (7).

VSGs that are successively expressed by an infecting population are antigenically distinct as a result of extreme sequence variation (3, 8). The structures of the N-terminal domains from two different VSGs (MITat1.2 and ILTat1.24) have been solved and are remarkably similar despite little sequence identity (9, 10). It is believed that the conservation of structure is necessary for the protective function of the VSG, although this has not been proven. The N-terminal domain of VSG MITat1.2 (9) is elongated and is composed of seven {alpha}-helices, which comprise about 47% of the structure. Two major {alpha}-helices, each of ~70 Å, form a coiled coil that acts as a scaffold for the remaining smaller helices and loops. The structure of VSG ILTat1.24 (10) is homologous to that of MITat1.2. Although the structural identity is 60%, the sequences are only 16% identical over the same residues. This striking conservation of structure is likely to be present in other VSGs (4, 1012) as well as some other cell surface proteins (13, 14).

The function of the VSG C-terminal domain remains obscure; it is possible that it elongates the VSG, resulting in a thicker surface coat, but this function is clearly not essential as neither T. congolense nor T. vivax VSGs contains an obvious equivalent of this domain. There is no obvious similarity between the VSG C-terminal domain sequence and any other protein, with the possible exception of an extracellular domain present in hexose transporters from trypanosomes and related species (13). The C-terminal domains from T. brucei-like VSGs are related to one another but can be split into four types based on sequence homology (3). In the structure of VSG MITat1.2, the N-terminal domain ends with an {alpha}-helix (helix S) which is followed by a single type 2 C-terminal domain in the native VSG. Type 2 C-terminal domains are characterized by 4 conserved cysteine residues. A similar arrangement of cysteines is present in type 1 C-terminal domains, where they are disulfide-bonded in a 1 to 3 and 2 to 4 pattern (15). When different type 2 C-terminal domains are compared, there is little sequence conservation other than the cysteines, a conserved hydrophobic (often aromatic) residue after the third cysteine and an N-linked glycosylation site very close to the C terminus (Fig. 1).



View larger version (110K):
[in this window]
[in a new window]
 
FIG. 1.
Sequence alignment of VSG type 2 C-terminal domains. The numbers along the top refer to the residue numbers of M1.2C. The secondary structure of M1.2C is shown along the top: {alpha}-helices are represented by yellow cylinders, the 310-helix by a gray cylinder, and {beta}-strands by yellow arrows. The conserved cysteines are boxed and highlighted in yellow; conserved hydrophobic residues are highlighted in green; conserved charged residues are blue (basic) or red (acidic). The C-terminal Asn that is glycosylated is boxed. For each VSG the label indicates (i) the species (Tbr, T. brucei; Tev, T. evansi; Teq, T. equiperdum) and the N- and C-terminal domain types (3); (ii) the EMBL accession number, and (iii) the VSG name, if available. The figure was produced using Alscript (37).

 
Progress in understanding the mechanism by which the VSG monolayer protects the trypanosome cell surface is largely dependent upon improving our knowledge of the complete structure of the VSG. This goal has been hindered by difficulties in obtaining high quality crystals of a complete VSG (16, 17). Here, we have reported the solution structure of the type 2 C-terminal domain from VSG MITat1.2 and thus the completion of the first structure of both domains of a VSG. The C-terminal domain has a novel structure and forms a compact fold of 42 residues, with a core comprised of 2 disulfide bonds and 2 conserved hydrophobic residues. Other divergent type 2 C-terminal domains have been modeled using the structure, indicating that the conservation of tertiary structure against a background of sequence variation is likely to be present in the VSG C-terminal domain as well as in the VSG N-terminal domain. The C-terminal domain structure has been used to produce a model of the VSG on the trypanosome cell surface that is consistent with a role for the C-terminal domain in the diffusion barrier function of the VSG.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Protein Expression and Purification—A construct designed to express residues 359–433 of mature VSG MITat1.2 (EMBL X56762 [GenBank] ) was cloned into the XhoI and BamHI sites of pET15b. The polypeptide was expressed either in Escherichia coli AD494(DE3) or in E. coli BL21trxB(DE3) in a minimal medium based on MOPS buffer, containing 5% 15N-labeled Celtone and [15N]ammonium chloride or 5% [13C,15N]Celtone, [15N]ammonium chloride, and [13C]glucose (Spectra Stable Isotopes). The C-terminal domain (M1.2C) was purified by affinity chromatography using a Ni2+ column followed by digestion with thrombin to remove the N-terminal His tag. After thrombin cleavage, 5 residues (GSHML) from the vector remained at the N terminus. M1.2C was further purified by gel filtration using a Superdex 30 column (Amersham Biosciences), followed by reverse-phase HPLC using a 25 x 1-cm Hichrom-5 C8 column and a 0–20% acetonitrile gradient in 0.1% trifluoroacetic acid. The presence of free sulfhydryls in M1.2C was measured using the Ellman assay (18) by reaction with 5,5'-dithiobis(2-nitrobenzoate). The relative molecular mass of M1.2C was determined by electrospray ion trap mass spectrometry.

Analytical Ultracentrifugation—Equilibrium sedimentation analysis was performed in a Beckman XL-I ultracentrifuge. Three two-sector cells were filled with 100 µl of 29, 30, or 37 µM M1.2C in 50 mM sodium phosphate, pH 6.0, and 150 mM NaCl; 110 µl of the same buffer was used on the reference side of each cell. The cells were placed in an An50-Ti rotor. For each sample, the equilibrium concentration gradients were measured for angular velocities of 25000, 33000, and 40000 rpm. Concentrations were measured as the absorbance at 280 nm (and using the Raleigh interference optics). The measured data were analyzed by global fitting using the program WinNonlin (19). The nine data sets were fitted simultaneously, with the molecular mass as a global parameter and with two local parameters for each (the concentration at the reference position and the baseline offset). The solvent density used was 1.01099 g/ml at 5 °C, and the protein partial specific volume at 5 °C was 0.6998 ml/g. Both values were calculated using Sednterp (T. Laue, University of New Hampshire). An extinction coefficient for the protein of 9098 M-1 cm-1 was obtained using amino acid analysis.

NMR Spectroscopy—NMR experiments were performed using [15N]- and [13C,15N]-labeled samples of 0.7–1.0 mM M1.2C in 50 mM sodium phosphate, pH 6.5, 150 mM sodium chloride, 10% D2O. Spectra were recorded at 25 °C on Bruker DRX 500 and DRX 600 spectrometers. The experiments recorded were 15N HSQC, 15N-separated NOESY (150 ms mixing time), 15N-separated TOCSY (67.9 ms DIPSI mixing), HNCA, HN(CO)CA, HNCACB, CBCA(CO)NH, HCCH-TOCSY, HBHA(CBCACO)NH, (H)CC(CO)NH-TOCSY (14.3 ms mixing time), 13C HSQC, and 13C-separated NOESY (150 ms mixing time). TALOS (20) was used to estimate backbone torsion angles based on the CA, CO, CB, N, and HA chemical shifts. CLEANEX (21) experiments were recorded to analyze solvent exchange rates and deduce hydrogen bonding information. Backbone dynamics were assessed using a heteronuclear NOE experiment (22). Spectra were processed using the program AZARA (W. Boucher, University of Cambridge) and analyzed with ANSIG (23).

Structure Calculations—Structure calculations were performed using ARIA (24) interfaced to CNS 1.0 (25). The structures were calculated with 90 ps of high temperature dynamics and 30 ps of cooling from 10,000 to 1,000 K in torsion angle space. This was followed by 24 ps of cooling from 1,000 to 50 K using dynamics in Cartesian space. Figs. 3, 5, and 6 were produced using Molscript (26) and Raster3d (27).



View larger version (49K):
[in this window]
[in a new window]
 
FIG. 3.
The structure of M1.2C. a, the backbone trace between Glu-376 and Asp-416 of the ensemble of 50 lowest energy structures of M1.2C. b, ribbon representation of the structure closest to the mean over the same residue range. The disulfide bonds are shown in yellow, and the residue numbers of the Cys residues involved are indicated.

 



View larger version (116K):
[in this window]
[in a new window]
 
FIG. 5.
Stabilization of the M1.2C core. The disulfide bonds are shown in yellow; the 2 conserved hydrophobic residues are green. The acidic and basic residues that appear to stabilize the C-terminal helix are red and blue, respectively.

 



View larger version (39K):
[in this window]
[in a new window]
 
FIG. 6.
Models of the C-terminal domains of MITat1.1 and ILTat1.21. a, the structure of MITat1.2. b, model of MITat1.1. c, model of ILTat1.21. The disulfide bonds are colored yellow. The residues that may stabilize the C-terminal helix are red (acidic), blue (basic), and pink (hydrophobic). The helix in ILTat1.21 is unlikely to continue after Glu-411, so although residues C-terminal to this were modeled as helix, they are colored white.

 
Homology Modeling—The structures of the C-terminal domains of MITat1.1 (EMBL accession number X56761 [GenBank] ) and ILTat1.21 (EMBL accession number X56766 [GenBank] ) were modeled using residues Ala-375 to Glu-417 of the closest structure to the mean of MITat1.2. The sequence alignment shown in Fig. 1 was used as the input for MODELLER (28). The model with the lowest MODELLER objective function was used for subsequent analysis after the stereochemistry was checked using PROCHECK (29).

Docking—The whole VSG structure was docked using the program 3D-Dock (30). The N-terminal domain dimer from MITat1.2 (Protein Data Bank code 1VSG [PDB] ) was docked with the core structure of the C-terminal domain (residues 375–416) on the basis of surface complementarity, and the resulting structures were then ranked on the basis of an empirical pair potential matrix (30).


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Purification of the MITat1.2 C-terminal Domain—A construct was designed to express a polypeptide containing the MITat1.2 C-terminal domain plus a short overlap with the N-terminal domain. The polypeptide (M1.2C) started at Glu-359, which is within helix S of the N-terminal domain (9), and ended at the mature C terminus, Ser-433. M1.2C was expressed in E. coli AD494(DE3) and E. coli BL21trxB(DE3); both strains carry a mutation in the trxB gene that allows the formation of protein disulfide bonds in the E. coli cytoplasm. M1.2C prepared from these strains contained no free sulfhydryl groups as determined by reaction with 5',5'-dithio-bis(2-nitrobenzoic acid). After thrombin cleavage, a relative molecular mass of 8730.61 ± 0.35 was determined by electrospray ion trap mass spectrometry, in agreement with the expected mass of 8730.4 for fully disulfide-bonded M1.2C.

Two-dimensional 1H TOCSY and NOESY experiments were recorded on unlabeled material that had been expressed in E. coli AD494(DE3). Some of the resonances in these spectra were accompanied by a second, weaker peak of about one-tenth the intensity. We concluded that these shadow cross-peaks were due to an alternative disulfide-bonded form of M1.2C because: (i) the electrospray ion trap mass spectrometry data indicated a homogeneous polypeptide of the expected mass, (ii) no free sulfhydryl groups were detected, and (iii) M1.2C appeared homogeneous by reducing SDS-PAGE but migrated as two close but distinct bands on non-reducing SDS-PAGE at a similar relative intensity to the two sets of resonances observed in the NMR spectra (data not shown). In subsequent experiments, the ratio of the two forms varied with the E. coli host strain, growth medium, and temperature of expression. The isotopically labeled samples were produced in E. coli BL21trxB(DE3), and it was necessary to purify the major form using reverse-phase HPLC. After HPLC purification, the intensity ratio of the resonances in a 15N HSQC spectrum was 11:1.

M1.2C Is a Monomer in Solution—VSGs are dimeric, and the N-terminal domain contains a large dimerization interface that buries ~8,000 Å2 (9). Equilibrium sedimentation analysis was used to determine whether the C-terminal domain is also a dimer (Fig. 2). The best fit of the model to the data gave a molecular mass of 8795 g/mol. When compared with the mass calculated from the amino acid composition of 8730.4 g/mol, it can be seen that M1.2C is a monomer in solution under the conditions used. The highest concentration used was 37 µM, so the Kd for any dimer formation would be >0.5 mM.



View larger version (43K):
[in this window]
[in a new window]
 
FIG. 2.
The equilibrium concentration gradients for M1.2C. The curves represent the values calculated based on the values obtained fitting to a single ideal species. The upper panel shows the residuals when subtracting the data from the fitted curve. The even distribution of these around zero indicates that the model describes the data well.

 
Three-dimensional Structure of M1.2C—Backbone resonances were assigned from HNCA, HN(CO)CA, HNCACB, and CBCA(CO)NH experiments using standard triple resonance techniques. Side chain assignments were completed using the 15N TOCSY, HCCH-TOCSY, HBHA(CBCACO)NH, and (H)C-C(CO)NH-TOCSY experiments. Assignment of NOEs was based on the 15N-separated NOESY (502 unambiguous, 100 ambiguous NOEs) and 13C-separated NOESY (509 unambiguous, 65 ambiguous NOEs). These NOEs were translated by ARIA into 719 unambiguous and 121 ambiguous, non-degenerate distance restraints. 24 pairs of dihedral restraints were derived from the backbone chemical shifts using TALOS-based predictions. 20 slowly exchanging amides were identified in the CLEANEX experiment, which were translated into hydrogen bond restraints within the secondary structure by manual inspection of structures generated by early rounds of structure calculations. The hydrogen bonds were treated as unambiguous NOEs, with distance restraints of 2.3 Å (O to H) and 3.3 Å (O to N). At the end of 8 iterations, there were 772 unambiguous and 97 ambiguous NOE-derived distance restraints. In the final iteration, 100 structures were calculated and the 50 lowest energy structures were used for further analysis.

The NMR data defined a structured core with unstructured residues at both the N and C termini. The structured part of M1.2C contained 42 residues from Ala-375 to Asp-416 (Fig. 3 and Table I). Each residue in this core region has a positive value for the heteronuclear NOE (Fig. 4). Outside the structured core, no long range distance restraints were observed for residues from Glu-359 to Ala-374 or from Glu-417 to Ser-433. The heteronuclear NOE values for these residues were less than 0.1 (Fig. 4), indicating that they are disordered in solution.


View this table:
[in this window]
[in a new window]
 
TABLE I
Experimental restraints and structural statistics

 



View larger version (47K):
[in this window]
[in a new window]
 
FIG. 4.
Relative flexibility of motion on a picosecond time scale for the backbone amides of M1.2C as indicated by the heteronuclear NOE values mapped against the residue number. The secondary structure of the domain is shown above the plot as cylinders and arrows for helices and {beta}-strands, respectively.

 
The initial structure calculations were performed with no disulfide restraints to attempt to determine the disulfide-bonding pattern by determining the distances between the S atoms in the cysteine residues (data not shown). This approach was inconclusive as all 4 cysteine residues were clustered together in the core (Figs. 3 and 5). The disulfide bonding pattern was subsequently elucidated by the identification of a strong NOE between the H{beta} of Cys-381 and Cys-393. This translates to a C{beta}–C{beta} interatomic distance of 3.497 Å in the structure closest to the mean, a value close to the canonical distance for two cysteines linked by a disulfide bond (31). No NOEs were observed between Cys-389 and Cys-404; their absence may be due to conformational exchange that leads to line broadening, as the backbone amide resonance of Cys-404 could not be observed in any NMR spectra. Interestingly, however, Cys-389 NH is observed and its heteronuclear NOE is typical of a structured residue. As there are no free thiols in the monomeric M1.2C and the relative molecular mass corresponds to the expected value for the fully disulfide-bonded form, Cys-389 and Cys-404 must also be forming a disulfide bond. Thus, M1.2C has a disulfide bonding pattern of 1 to 3 and 2 to 4, the same as that present in VSG type 1 C-terminal domains (15).

The secondary structure of M1.2C (Fig. 2) begins with a short {alpha}-helix between residues Glu-378 and Lys-383. This is followed by a single turn of 310-helix between residues Gln-386 and Glu-388, which is connected by a short loop to the first strand of the {beta}-sheet from Cys-393 to His-396. The two short strands of the {beta}-sheet result in a typical network of interstrand NOEs and hydrogen bonds. The second strand of the {beta}-sheet runs from Lys-403 to Leu-406 and leads to a longer {alpha}-helix stretching from Lys-408 to Asp-416. As well as the usual intrahelix NOE pattern, this terminal {alpha}-helix has a limited number of long range NOEs to the rest of the core region, in agreement with the lower heteronuclear NOE values for this region (Fig. 4).

The loop, Asn-397 to Lys-402, connecting the two {beta}-strands is not well defined (at the top of the structure in Fig. 3) with the heteronuclear NOE values ranging between 0.3 and 0.6, lower than for most of the structured core (Fig. 4). The line widths of the resonances corresponding to residues within this loop were also larger than the average line width in the core, implying that there is motion on the millisecond time scale within this region.

The heteronuclear NOE values for the C-terminal {alpha}-helix (Lys-408 to Asp-416) are positive but decrease toward the terminus, suggesting that there is an increase in the amplitude of helix motion. The majority of residues in the {alpha}-helix are charged (Fig. 1), and it appears to be stabilized by a number of salt bridges (Fig. 5) both within the helix and between the helix and the rest of the domain. In the middle of the helix, Lys-412 makes a salt bridge with Asp-416 and Lys-413 is sandwiched between Glu-409 and Glu-417. The spacing between these residues conforms to the i, i+4 pattern that has been observed to stabilize isolated {alpha}-helices (32). Two sets of ionic interactions between the C-terminal {alpha}-helix and other residues in the structured core pin the N terminus of the helix to the rest of the core: Lys-394 in the first {beta}-strand interacts with Asp-407 and Glu-410, whereas Glu-378 in the first {alpha}-helix interacts with Lys-408 (Fig. 5).

The 4 cysteines in M1.2C lie buried in the core of the structure (Fig. 5). The remainder of the core is composed of 2 hydrophobic residues that flank the disulfide bonds, Trp-395 and Leu-406. These residues, as well as the cysteines, are conserved in many VSG type 2 C-terminal domains (Fig. 1); in other type 2 C-terminal domains hydrophobic residues are usually found at an equivalent location in the sequence. Most of the remainder of the domain is made up of small polar and charged residues, with the exception of Pro-392, which also makes hydrophobic contacts with Ala-411 and Val-414 in the C-terminal helix. None of these 3 residues is conserved in type 2 C-terminal domains.

The importance of the cysteines for the structural integrity of M1.2C was tested by making mutants in which the cysteines were changed to alanines. Three mutants were made: (i) C381A and C393A, (ii) C389A and C404A, and (iii) all four cysteines mutated to alanine. The proteins were expressed, purified, and preliminary 1H NMR spectra collected. The spectra of all three mutants showed considerably less dispersion of resonances (data not shown), indicating that none of them retains the structure of wild-type M1.2C.

Comparison with Other Structures—The structure of the M1.2C does not bear direct homology to any known structure in the Protein Data Bank, according to a search performed using the Dali server (33). Comparison with other small, disulfiderich structures suggests that the C-terminal domain is similar to Knottins and Trefoil fold proteins. The Knottins are a diverse group of proteins with a common structural motif comprising a {beta}-hairpin with a cysteine on each side that forms disulfide bonds with cysteines outside the hairpin (34). In Knottins, however, the cysteine residues in the hairpin are usually directly opposite each other, whereas in M1.2C the equivalent cysteines (Cys-393 and Cys-404) are staggered (Figs. 3 and 5). A similar staggered arrangement otherwise only occurs in the Trefoil fold (for example Protein Data Bank 1e9t [PDB] and 1ps2). Although the Trefoil fold contains three disulfide bonds, it appears to be the nearest, but remote, structural neighbor of M1.2C.

Modeling of the Structures of Other VSG Type 2 C-terminal Domains—The structure of M1.2C was used to model the VSG type 2 C-terminal domains from VSGs MITat1.1 and ILTat1.21 (Fig. 6). These sequences were selected as examples of C-terminal domains that are increasingly divergent from the sequence of MITat1.2 (Fig. 1). The C-terminal domain of MITat1.1 has a higher degree of identity to M1.2C than ILTat1.21, which is among the most divergent from M1.2C. The divergence is most apparent in the region of ILTat1.21 corresponding to the second {alpha}-helix in M1.2C; only 2 of the 9 residues are charged in ILTat1.21 compared with the 6 in M1.2C. It is not clear whether this region of ILTat1.21 will form an {alpha}-helix as is found in M1.2C. Both of the domains modeled have the 2 hydrophobic residues that stabilize each side of the core, performing a function equivalent to Trp-395 and Leu-406 in MITat1.2 (Figs. 1 and 5), Phe-407 and Leu-416 in MITat1.1, Tyr-397 and Pro-406 in ILTat1.21. The models were of good stereochemical quality, as determined by PROCHECK (data not shown).

In the model of MITat1.1, the C-terminal helix is likely to be stabilized in a similar way to that of M1.2C (Fig. 6). In several places along the helix, the charges are reversed with respect to those in M1.2C, and in these cases the charge of the interacting residue is also reversed. For example, in MITat1.2, Lys-412 and Asp-416 are close together on the surface of the helix, whereas in MITat1.1 these residues are replaced by Glu-422 and Lys-426, respectively. The model predicts that the C-terminal helix in MITat1.1 will be stabilized by interactions between Lys-423 and Asp-419/Glu-427, between Lys-417 and Asp-419, and between Glu-384 and Lys-418 (Fig. 6b). There are also two hydrophobic side chains within this helix in MITat1.1, Val-420 and Leu-424, which are on the same side of the helix. These residues are stabilized by a hydrophobic interaction with Leu-400 (Fig. 6b) within the loop before the first {beta}-strand, which is longer in MITat1.1 than MITat1.2, so that Leu-400 corresponds to a gap in the alignment (Fig. 1). These considerations suggest that MITat1.1 can form the same structured core as MITat1.2. The C-terminal helix can be stabilized by ion pairs in a similar way, with extra stabilization coming from hydrophobic interactions.

In contrast, in ILTat1.21 the C-terminal helix has almost no charged residues, although those that are present can make stabilizing interactions (Fig. 6c). Thus, Lys-408 and Glu-411 could interact, as could Glu-396 and Lys-407. The remainder of this helix is made up of small, uncharged residues. The charged residues that are present are at the N terminus of the helix, so it is likely that ILTat1.21 will form a shorter helix here, of a single turn. The interaction between Lys-408 and Glu-411 would favor 310-helix formation as this would bring these side chains into close proximity.

Model of a Complete VSG Polypeptide—The program 3D-Dock (30) was used to produce a model of the complete VSG polypeptide (Fig. 7). This model was selected by filtering the output for (i) the surface complementarity and an empirical likelihood that certain residues interact, (ii) the position of the C-terminal domain at the membrane-proximal end of the N-terminal domain, (iii) a structure that was consistent with the envelope determined for the C-terminal domain of VSG ILTat1.24 (17), and (iv) a structure that had the C terminus pointing down toward the location of the plasma membrane and the glycosylphosphatidylinositol anchor. The model shown was the highest ranked that met these criteria.



View larger version (72K):
[in this window]
[in a new window]
 
FIG. 7.
Model of the complete VSG MITat1.2 dimer. The two N-terminal domains are shown in green and pink and the two C-terminal domains in blue. The dashed white line in one of the monomers represents the 15-residue protease-sensitive linker between the two domains. There are an additional 16 residues containing an N-linked glycosylation site between the C terminus of the model and the ethanolamine of the glycosylphosphatidylinositol anchor.

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The VSG monolayer that covers the cell surface of trypanosomes in a mammal is the molecular interface between host and parasite and has evolved to facilitate the long term persistence of an infection. VSGs are subject to two evolutionary pressures, sequence variation for antigenic variation and conservation of tertiary structure, which is assumed necessary for the protective function of the VSG. An understanding of the molecular mechanism by which the VSG is able to protect other cell surface components from the host immune system is dependent on knowledge of the VSG structure.

Here, we have presented the first structure of a VSG C-terminal domain. The structure is novel and has at its core a pair of disulfide bonds. In the absence of either pair of cysteines, the domain does not fold correctly, and thus both disulfide bonds are required to form the structure. The requirement for both disulfide bonds is consistent with the absolute conservation of 4 cysteines in all other VSG type 2 C-terminal domains. The isolated domain is a monomer in solution, so the native VSG dimerizes through interactions between the N-terminal domains of the monomers. However, it is not possible to rule out interactions between the C-terminal domains at the exceptionally high concentrations of VSG present on the trypanosome surface.

The VSG C-terminal domain is comprised of a compact core of 42 residues, Ala-375 to Asp-416, flanked by two unstructured regions. To the C-terminal side of this core, the unstructured residues, Glu-417 to Ser-433 (Fig. 1), are polar and in native MITat1.2 contain an N-linked glycan on Asn-429 and the glycosylphosphatidylinositol anchor oligosaccharide on the carboxyl group of Ser-433. It is possible that the absence of the carbohydrate in the recombinant polypeptide used for the structural studies resulted in destabilization of the structure in this region. However, it is more likely that in the native VSG this part of the protein is flexible as the N-linked oligosaccharide can be either an oligomannose containing 7–9 mannose residues or a branched poly-N-acetyllactosamine (35). The diversity in the oligosaccharide suggests that this region of the protein has to be flexible to accommodate a range of sugar moieties. To the N-terminal side of the core, the unstructured residues, Glu-359 to Ala-374, include the protease-sensitive "hinge" between the two domains (2, 15). The construct used for the structural studies contained a 4-residue overlap, Glu-359 to Thr-362, with the structured VSG N-terminal domain (Ala-1 to Thr-362) (9). The objective of the overlap was to at least define the limits of the unstructured hinge and possibly to overlap the two structures to produce a model of the structure of a whole VSG. The maximum limits of the unstructured hinge are the 15 residues Gln-363 to Thr-377, as Thr-362 is structured in the N-terminal domain and the secondary structure of the C-terminal domain begins at Glu-378.

The second finding in this study was the demonstration that the structure of M1.2C can be used to produce models of other VSG type 2 C-terminal domains. The different type 2 C-terminal domains have the 4 conserved cysteines and 2 conserved hydrophobic residues that make up the core of the domain; otherwise they have little conservation of sequence except around the N-linked glycosylation site close to the C terminus (Fig. 1). The conservation of tertiary structure mirrors that previously found in the N-terminal domain and is presumably necessary for the function of the VSG C-terminal domain.

It has been proposed that the function of the VSG C-terminal domain is to increase the ability of the VSG monolayer to protect underlying proteins from host immunoglobulins, possibly by simply increasing the thickness of the monolayer (36). However, the C-terminal domain is a compact structure and the N and C termini of the domain are relatively close to each other. Thus, the domain is not particularly extended as might be expected of a domain with such a structural role in increasing the thickness of the VSG monolayer. The model of the VSG (Fig. 7) suggests that the VSG is not particularly extended by the inclusion of the C-terminal domain but does suggest that the C-terminal domain contributes to a densely packed polypeptide layer proximal to the plasma membrane.

The VSG coat has evolved to ensure the long term survival of an infecting population by functioning both in antigenic variation and in the formation of a protective macromolecular diffusion barrier. The results presented herein suggest that the C-terminal domain contributes to the diffusion barrier by creating a region densely packed with polypeptide adjacent to the plasma membrane.


    FOOTNOTES
 
The atomic coordinates and structure factors (code 1XU6) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

* This work was supported by the Wellcome Trust. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ Recipient of a Nehru Fellowship from the Cambridge Commonwealth Trust. Back

||To whom correspondence may be addressed. Tel.: 44-1223-766018; Fax: 44-1223-766002; E-mail: h.r.mott{at}bioc.cam.ac.uk. **To whom correspondence may be addressed. Tel.: 44-1223-333683; Fax: 44-1223-766002; E-mail: mc115{at}cam.ac.uk.

1 The abbreviations used are: VSG, variant surface glycoprotein; TOCSY, total correlation spectroscopy; NOE, nuclear Overhauser effect; NOESY, NOE spectroscopy; HSQC, heteronuclear single quantum correlation; HPLC, high performance liquid chromatography; MOPS, 4-morpholinepropanesulfonic acid. Back


    ACKNOWLEDGMENTS
 
We thank Alexey Murzin and Dave Barry for helpful discussions. Mass spectrometry and initial disulfide analysis was carried out by the Protein and Nucleic Acid Chemistry group, Department of Biochemistry, University of Cambridge. This was a contribution from the Cambridge Center for Molecular Recognition, supported by the Biotechnology and Biological Sciences Research Council and the Wellcome Trust.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. McCulloch, R. (2004) Trends Parasitol. 20, 117-121[CrossRef][Medline] [Order article via Infotrieve]
  2. Johnson, J. G., and Cross, G. A. M. (1979) Biochem. J. 178, 689-697[Medline] [Order article via Infotrieve]
  3. Carrington, M., Miller, N., Blum, M., Roditi, I., Wiley, D., and Turner, M. (1991) J. Mol. Biol. 221, 823-835[CrossRef][Medline] [Order article via Infotrieve]
  4. Bussler, H., Linder, M., Linder, D., and Reinwald, E. (1998) J. Biol. Chem. 273, 32582-32586[Abstract/Free Full Text]
  5. Auffret, C. A., and Turner, M. J. (1981) Biochem. J. 193, 647-650[Medline] [Order article via Infotrieve]
  6. Strickler, J. E., and Patton, C. L. (1982) Exp. Parasitol. 53, 117-132[CrossRef][Medline] [Order article via Infotrieve]
  7. Ferguson, M. A., Homans, S. W., Dwek, R. A., and Rademacher, T. W. (1988) Science 239, 753-759[Abstract/Free Full Text]
  8. Cross, G. A. M. (1975) Parasitology 71, 393-417[Medline] [Order article via Infotrieve]
  9. Freymann, D., Down, J., Carrington, M., Roditi, I., Turner, M., and Wiley, D. (1990) J. Mol. Biol. 216, 141-160[CrossRef][Medline] [Order article via Infotrieve]
  10. Blum, M. L., Down, J. A., Gurnett, A. M., Carrington, M., Turner, M. J., and Wiley, D. C. (1993) Nature 362, 603-609[CrossRef][Medline] [Order article via Infotrieve]
  11. Mehlert, A., Bond, C. S., and Ferguson, M. A. J. (2002) Glycobiology 12, 607-612[Abstract/Free Full Text]
  12. Campillo, N., and Carrington, M. (2003) Mol. Biochem. Parasitol. 127, 79-84[CrossRef][Medline] [Order article via Infotrieve]
  13. Carrington, M., and Boothroyd, J. (1996) Mol. Biochem. Parasitol. 81, 119-126[CrossRef][Medline] [Order article via Infotrieve]
  14. Salmon, D., Hanocq-Quertier, J., Paturiaux-Hanocq, F., Pays, A., Tebabi, P., Nolan, D. P., Michel, A., and Pays, E. (1997) EMBO J. 16, 7272-7278[CrossRef][Medline] [Order article via Infotrieve]
  15. Allen, G., and Gurnett, L. P. (1983) Biochem. J. 209, 481-487[Medline] [Order article via Infotrieve]
  16. Down, J., Garman, S., Gurnett, A., Turner, M., and Wiley, D. (1991) J. Mol. Biol. 218, 679-683[CrossRef][Medline] [Order article via Infotrieve]
  17. Garman, S. C. (1994) The X-ray Crystallographic Analysis of an Intact VSG from the Trypanosome. Ph.D. thesis, Harvard University, Cambridge, Massachusetts
  18. Sedlak, J., and Lindsay, R. M. (1968) Anal. Biochem. 25, 192-205[CrossRef][Medline] [Order article via Infotrieve]
  19. Johnson, M. L., Correia, J. J., Yphantis, D. A., and Halvorson, H. R. (1981) Biophys. J. 36, 575-588[Abstract/Free Full Text]
  20. Cornilescu, G., Delaglio, F., and Bax, A. (1999) J. Biomol. NMR 13, 289-302[CrossRef][Medline] [Order article via Infotrieve]
  21. Hwang, T. L., van Zijl, P. C. M., and Mori, S. (1998) J. Biomol. NMR 11, 221-226[CrossRef][Medline] [Order article via Infotrieve]
  22. Farrow, N. A., Zhang, O. W., Forman-Kay, J. D., and Kay, L. E. (1995) Biochemistry 34, 868-878[CrossRef][Medline] [Order article via Infotrieve]
  23. Kraulis, P. J., Dommaile, P. J., Campbell-Burk, S. L., Aken, T. V., and Laue, E. D. (1994) Biochemistry 33, 3515-3531[CrossRef][Medline] [Order article via Infotrieve]
  24. Linge, J. P., O'Donoghue, S. J., and Nilges, M. (2001) Methods Enzymol. 339, 71-90[CrossRef][Medline] [Order article via Infotrieve]
  25. Brunger, A. T., Adams, P. D., Clore, G. M., Delano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 905-921[CrossRef][Medline] [Order article via Infotrieve]
  26. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 627-633
  27. Merritt, E. A., and Bacon, D. J. (1997) Methods Enzymol. 277, 505-524[Medline] [Order article via Infotrieve]
  28. Marti-Renom, M., Stuart, A., Fiser, A., Sanchez, R., Melo, F., and Sali, A. (2000) Annu. Rev. Biophys. Biomol. Struct. 29, 291-325[CrossRef][Medline] [Order article via Infotrieve]
  29. Laskowski, R., MacArthur, M., Moss, D., and Thornton, J. (1993) J. Appl. Crystallogr. 26, 283-291[CrossRef]
  30. Moont, G., Gabb, H. A., and Sternberg, M. J. E. (1999) Proteins Struct. Funct. Genet. 35, 364-373[CrossRef][Medline] [Order article via Infotrieve]
  31. Klaus, W., Broger, C., Gerber, P., and Senn, H. (1993) J. Mol. Biol. 232, 897-906[CrossRef][Medline] [Order article via Infotrieve]
  32. Lyu, P. C., Gans, P. J., and Kallenbach, N. R. (1992) J. Mol. Biol. 223, 343-350[CrossRef][Medline] [Order article via Infotrieve]
  33. Holm, L., and Sander, C. (1998) Nucleic Acids Res. 26, 316-319[Abstract/Free Full Text]
  34. Gelly, J. C., Gracy, J., Kaas, Q., Le-Nguyen, D., Heitz, A., and Chiche, L. (2004) Nucleic Acids Res. 32, D156-D159[Abstract/Free Full Text]
  35. Zamze, S. E., Ashford, D. A., Wooten, E. W., Rademacher, T. W., and Dwek, R. A. (1991) J. Biol. Chem. 266, 20244-20261[Abstract/Free Full Text]
  36. Ziegelbauer, K., and Overath, P. (1993) Infect. Immun. 61, 4540-4545[Abstract/Free Full Text]
  37. Barton, G. J. (1993) Protein Eng. 6, 37-40[Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Genome ResHome page
L. Marcello and J. D. Barry
Analysis of the VSG gene silent archive in Trypanosoma brucei reveals that mosaic gene expression is prominent in antigenic variation and is favored by archive substructure
Genome Res., September 1, 2007; 17(9): 1344 - 1352.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/8/7228    most recent
M410787200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chattopadhyay, A.
Right arrow Articles by Carrington, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chattopadhyay, A.
Right arrow Articles by Carrington, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.